Skip to content
HomeMedia CenterPress releases Medical technologiesJohnson & Johnson MedTech working with NVIDIA to scale AI for surgery

Johnson & Johnson MedTech working with NVIDIA to scale AI for surgery

Johnson & Johnson MedTech is working with NVIDIA on how its technologies can accelerate secure, real-time analysis of surgical data at the edge

Johnson & Johnson MedTech will enable AI-based model development and application deployment, providing a path to scale within its connected digital ecosystem for surgery

Share Article
share to

March 18, 2024 – New Brunswick, New Jersey – Johnson & Johnson MedTech today announced it is working to accelerate and scale artificial intelligence (AI) for surgery with NVIDIA, supporting increased access to real-time analysis and global availability of AI algorithms for surgical decision-making, education, and collaboration across the connected operating room (OR).

The companies executed a memorandum of understanding to accelerate AI for Johnson & Johnson MedTech’s extensive surgical technologies portfolio with NVIDIA’s AI platform for healthcare. The technologies are designed to allow for fast, secure, and real-time AI deployment through Johnson & Johnson MedTech’s digital surgery ecosystem.

“Johnson & Johnson MedTech is advancing healthcare toward a future that’s more connected and personalized,” said Tim Schmid, Executive Vice President, and Worldwide Chairman, MedTech. “This future will be increasingly enabled by digital technologies that deliver efficiency, inform decision-making, and extend surgical training and education. Our deep heritage in healthcare and digital ecosystem in surgery and NVIDIA’s AI platforms hold enormous potential to create a more connected surgical experience.”

A key element of accelerating AI for surgery is advanced edge computing to allow for localized data processing within the OR, a necessary step for AI algorithms to analyze live and stored surgical data in real time. The approach can also help reduce the need for the transfer of sensitive data and allow for specific applications to run separately within the secure computing environment, delivering ultra-low latency within the operating room, where every second matters.

The NVIDIA IGX edge computing platform and the NVIDIA Holoscan edge AI platform create infrastructure to deploy AI-powered software applications in the OR.

Johnson & Johnson MedTech will also leverage AI technologies to extend its open ecosystem for surgery. NVIDIA’s purpose-built solutions are designed to help accelerate innovation throughout the ecosystem and speed the development and deployment of AI-powered applications in a secure and scalable manner.

“One of the major challenges in scaling AI for surgery is the closed design of surgical technologies,” said Shan Jegatheeswaran, Vice President and Global Head of Digital, MedTech. “Bringing advanced edge computing hardware and software to the OR enables scalability of innovation and new AI-powered solutions for clinical decision-making, education and training, and collaboration – with the ultimate goal of advancing patient care.”

About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we are working to solve the world’s most pressing healthcare challenges through innovations at the intersection of biology and technology. We harness our deep expertise in surgery, orthopedics, vision, and interventional solutions to design healthcare solutions that are smarter, less invasive, and more personalized. To learn more about how we develop med tech that helps save lives and redefine what it feels like to be a patient, visit

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the Memorandum of Understanding with NVIDIA. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Ethicon, Inc., Auris Health, Inc. and/or Johnson & Johnson (the “Company”). Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges in new product development; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. None of Ethicon, Inc., Auris Health, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.


Media contact:
Ryan Carbain
(732) 232-9062

You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.